Premature Labor (Tocolysis) - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 52

Premature Labor (Tocolysis) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Premature Labor (Tocolysis) - Pipeline Review, H1 2012', provides an overview of the Premature Labor (Tocolysis) therapeutic pipeline. This report provides information on the therapeutic development for Premature Labor (Tocolysis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis). 'Premature Labor (Tocolysis) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Premature Labor (Tocolysis).
- A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Premature Labor (Tocolysis) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Premature Labor (Tocolysis) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Premature Labor (Tocolysis) Therapeutic Products under Development, Key Players in Premature Labor (Tocolysis) Therapeutics, Premature Labor (Tocolysis) Pipeline Overview, Premature Labor (Tocolysis) Pipeline, Premature Labor (Tocolysis) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) Overview
Therapeutics Development
An Overview of Pipeline Products for Premature Labor (Tocolysis)
Premature Labor (Tocolysis) Therapeutics under Development by Companies
Premature Labor (Tocolysis) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Premature Labor (Tocolysis) Therapeutics – Products under Development by Companies
Premature Labor (Tocolysis) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Premature Labor (Tocolysis) Therapeutics Development
GlaxoSmithKline plc
Watson Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
PDC Biotech GmbH
Ferring Pharmaceuticals, Inc.
Premature Labor (Tocolysis) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Retosiban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MN-221 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prochieve 8% - Drug Profile
Product Description
Mechanism of Action
R&D Progress
17-Alpha Hydroxyprogesterone Caproate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Micronized Progesterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Barusiban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nifedipine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nifedipine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Indomethacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Labor (Tocolysis) Therapeutics – Drug Profile Updates
Premature Labor (Tocolysis) Therapeutics – Discontinued Products
Premature Labor (Tocolysis) Therapeutics - Dormant Products
Premature Labor (Tocolysis) – Product Development Milestones
Featured News & Press Releases
Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8%
Feb 09, 2012: Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories
Jan 20, 2012: FDA Advisory Committee Declines To Recommend Approval Of Watson's Progesterone Vaginal Gel 8% For Reduction Of Risk Of Preterm Birth In Women With Short Uterine Cervical Length
Nov 10, 2011: Columbia Laboratories And Watson Pharmaceuticals Confirm FDA Advisory Committee To Review Preterm Birth NDA
Jun 27, 2011: Columbia Laboratories' NDA For PROCHIEVE Vaginal Progesterone Gel Accepted For Filing By FDA
Apr 26, 2011: Columbia Laboratories Submits NDA For PROCHIEVE Vaginal Progesterone Gel
Apr 06, 2011: Columbia And Watson Announce Publication Of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results
Feb 04, 2011: K-V Pharmaceutical Announces FDA Approval For Makena
Apr 21, 2010: Swedish Orphan Biovitrum To Initiate Phase III Trial For Kiobrina
Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Premature Labor (Tocolysis), H1 2012
Products under Development for Premature Labor (Tocolysis) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
GlaxoSmithKline plc, H1 2012
Watson Pharmaceuticals, Inc., H1 2012
Kissei Pharmaceutical Co., Ltd., H1 2012
PDC Biotech GmbH, H1 2012
Ferring Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Premature Labor (Tocolysis) Therapeutics – Drug Profile Updates
Premature Labor (Tocolysis) Therapeutics – Discontinued Products
Premature Labor (Tocolysis) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Premature Labor (Tocolysis), H1 2012
Products under Development for Premature Labor (Tocolysis) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Premature Ejaculation – Pipeline Review, H1 2013
• Premature Ejaculation - Pipeline Review, H1 2012
• Premature Ejaculation - Pipeline Review, H2 2012
• Candidiasis - Pipeline Review, H1 2013
• Premature Ejaculation - Pipeline Review, H2 2011
• Male Sexual Dysfunction - Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Rhinitis - Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013